![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Dr. Reddy's in Clinical Trials for Cardio Compound in Ireland
Dr. Reddy's in Clinical Trials for Cardio Compound in Ireland
Indian drugmaker Dr. Reddy's has begun Phase I clinical trials for a new compound, known as RUS 3108, to treat atherosclerosis, a significant cause of cardiovascular events such as heart attack and stroke. The company claims that the prospective drug, currently under study at its facility in Ireland, induces a protein called perlecan. This substance purportedly alleviates conditions associated with the artery-hardening condition.
Dr. Reddy's, like many Indian drugmakers, has expanded heavily in R&D in recent years as it diversifies away from its origins in the generics sector. The company now claims to have six new chemical entities under development.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct